imfinzi
astrazeneca ab - durvalumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
tracrium süste-/infusioonilahus
aspen pharma trading limited - atrakuuriumbesilaat - süste-/infusioonilahus - 10mg 1ml 5ml 5tk; 10mg 1ml 2.5ml 5tk
raploc infusioonilahuse pulber
amomed pharma gmbh - landiolool - infusioonilahuse pulber - 300mg 1tk
raploc infusioonilahuse pulber
amomed pharma gmbh - landiolool - infusioonilahuse pulber - 600mg 1tk
esmocard lyo infusioonilahuse kontsentraadi pulber
orpha-devel handels und vertriebs gmbh - esmolool - infusioonilahuse kontsentraadi pulber - 2500mg 1viaal